Jie-nan Zhou - Infectious Diseases

Author Information

Jie Zhou is a prominent researcher in the field of infectious diseases, particularly focusing on the study of SARS-CoV-2 and other viral pathogens. Jie Zhou is affiliated with the Department of Microbiology at The University of Hong Kong, and is also associated with the State Key Laboratory of Emerging Infectious Diseases and the Research Centre of Infection and Immunology in Hong Kong. This affiliation highlights Jie Zhou's significant contribution to the understanding and management of emerging infectious diseases through both academic and applied research.

Research Contributions

Jie Zhou has made substantial contributions to the field of infectious diseases, particularly in the context of the SARS-CoV-2 pandemic. The research includes studying the safety and viral kinetics of SARS-CoV-2, exploring the effects of different adjuvants on immune responses to vaccines, and examining the implications of genetic mutations in virus adaptation and pathogenicity. Significant work has also been done on the replication and immune evasion of various SARS-CoV-2 variants, such as Omicron and Delta. Additionally, Jie Zhou has contributed to understanding the interaction between viral pathogens and host immune responses, as seen in research on Zika virus and enteroviruses, using advanced models like three-dimensional human intestinal organoids.

Aliases

Jie Zhou is also known by the alias Jie-nan Zhou, which may appear in some academic publications or records.

Publication and Citation Metrics

Metric	Value
Total Papers	151
Total Citations	11,727
h-index	48

Publications:

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge

DOI: 10.21203/rs.3.rs-1121993/v1

Year: 2022

Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant

DOI: 10.3390/v14030501

Year: 2022

Mutations that adapt SARS-CoV-2 to mink or ferret do not increase fitness in the human airway

DOI: 10.1016/j.celrep.2022.110344

Year: 2022

The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry

DOI: 10.1101/2021.12.31.474653

Year: 2022

Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron.

DOI: 10.1038/s41586-022-04442-5

Year: 2022

STAT2-dependent restriction of Zika virus by human macrophages but not dendritic cells

DOI: 10.1080/22221751.2021.1929503

Year: 2021

Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation

DOI: 10.1038/s41392-021-00712-2

Year: 2021

Emerging SARS-CoV-2 variants expand species tropism to rodents

DOI: 10.21203/RS.3.RS-676992/V1

Year: 2021

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

DOI: 10.1038/s41586-021-03944-y

Year: 2021

Development of Three-Dimensional Human Intestinal Organoids as a Physiologically Relevant Model for Characterizing the Viral Replication Kinetics and Antiviral Susceptibility of Enteroviruses

DOI: 10.3390/biomedicines9010088

Year: 2021

What Are Some Common Resistant Bacteria?

What is the Role of Pharmacovigilance?

What are the Risk Factors for HAIs?

When to Use Decongestants?

Why are Zoonotic Diseases Important?

How Do Infectious Diseases Impact Public Health?

What are the Symptoms of Chlamydia?

Is There a Vaccine for Yellow Fever?

How Are These Diseases Diagnosed?

What Role Does Technology Play in Personalized Medicine?

Partnered Content Networks

Relevant Topics